Clarient
Clarient is a US-based precision oncology diagnostics company founded in 1993 and headquartered in Aliso Viejo, California, providing multi-modal cancer testing and diagnostic services to oncologists, pathologists, hospitals, and biopharma partners across the United States.
- Company typePublic
- Founded2001
- HeadquartersAliso Viejo, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Clarient does
Clarient is a US-based precision oncology diagnostics company headquartered in Aliso Viejo, California. Founded in 1993, the company provides cancer testing and diagnostic services to oncologists, pathologists, hospitals, and other healthcare providers across the United States, with a workforce of 251-500 employees. The firm operates as a private, for-profit entity.
The diagnostic platform integrates multiple testing modalities — single-gene molecular testing, immunohistochemistry (IHC), flow cytometry, fluorescence in situ hybridization (FISH), DNA- and RNA-based next-generation sequencing (NGS), and comprehensive genomic profiling (CGP) — across both solid tumor and hematologic cancer workflows. Proprietary assets include the RaDaR ST tumor-personalized minimal residual disease (MRD) detection assay and the PanTracer / PanTracer Pro comprehensive genomic profiling portfolio, both registered trademarks. The broader operational footprint referenced in the input (over 500 tests, 40,000+ unique providers, 4,000+ healthcare organizations, and a 2M+ patient profile real-world evidence dataset) reflects the integrated platform following Clarient's 2015 acquisition by NeoGenomics Laboratories; these specific operational figures should not be attributed to Clarient as a standalone entity without independent verification.
The go-to-market is enterprise sales-led, targeting large healthcare systems and oncology practices via direct provider relationships, EHR-integrated ordering and result delivery, and dedicated client support. Revenue is generated through fee-for-service laboratory testing under contracted or quote-based pricing with providers and health insurance plans, supplemented by a biopharma services vertical spanning biomarker discovery, clinical trial support, regulatory support, and oncology data solutions. Historical Clarient strategic activity includes a $40M funding round led by Oak Investment Partners in May 2009, a $10.9M financing in December 2009, and the December 2009 acquisition of Applied Genomics.
Clarient firmographics
Firmographics- Name
- Clarient
- Legal name
- NeoGenomics Laboratories
- Website
- https://clarientinc.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Clarient is a US-based precision oncology diagnostics company founded in 1993 and headquartered in Aliso Viejo, California, providing multi-modal cancer testing and diagnostic services to oncologists, pathologists, hospitals, and biopharma partners across the United States.
- Ownership category
- akta.pro rank
Clarient industry classification
Industry- Product category
- Oncology Diagnostic Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Clarient is headquartered
LocationHeadquarters
- HQ city
- Aliso Viejo
- HQ country
- United States
- HQ region
- North America
Markets served
Clarient business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Laboratory Testing Services: NeoGenomics generates revenue through providing oncology laboratory testing services to healthcare providers. The company offers over 500 tests across multiple modalities including molecular testing, immunohistochemistry, flow cytometry, FISH, NGS, and comprehensive genomic profiling. Testing services cover both solid tumors and hematologic cancers through tissue-based, liquid biopsy, and heme tests.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Clarient product offering
Product offeringCore offering
Clarient provides oncology testing and diagnostic services in the United States, operating as a precision oncology laboratory within NeoGenomics Laboratories. The company offers over 500 tests across major modalities — including molecular testing, immunohistochemistry (IHC), flow cytometry, FISH, DNA/RNA next-generation sequencing (NGS), and comprehensive genomic profiling (CGP) — covering both solid tumors and hematologic cancers through tissue-based, liquid biopsy, and heme tests. It supports healthcare providers with diagnostic data, therapy guidance, and predictive biomarker insights, and partners with biopharma on drug development, biomarker discovery, and clinical trial services.
Product overview
NeoGenomics Laboratories is a precision oncology diagnostics company offering a broad platform of cancer testing solutions. The portfolio includes disease-state specific testing products (RaDaR ST for MRD detection, PanTracer Portfolio, and cancer-specific panels for lung, breast, colorectal, gastric, gynecologic, and hematologic cancers) supported by multiple testing modalities (single-gene molecular testing, immunohistochemistry, flow cytometry, FISH, NGS, and comprehensive genomic profiling). The company provides over 500 tests across tissue-based, liquid biopsy, and heme testing types. Services include biopharma partnership programs, oncology data solutions leveraging real-world evidence from millions of patient profiles, regulatory support, and pathology lab services. The offering functions as an integrated diagnostics platform spanning test development, laboratory services, data analytics, and biopharma collaboration.
Differentiator
Problem solved
Functional benefit
Brands
- RaDaR ST: Minimal Residual Disease (MRD) detection technology personalized to each patient's tumor
- PanTracer
- PanTracer Pro
Products and services
- RaDaR ST Minimal Residual Disease (MRD) detection test personalized to every patient's tumor, designed to detect residual disease signals at the earliest stage and monitor treatment response.
- PanTracer Portfolio Comprehensive genomic and biomarker testing portfolio providing genomic and biomarker insights tailored to patients for personalized therapy selection in one streamlined order.
- Lung Cancer Testing Lung cancer molecular profiling and biomarker testing for personalized treatment selection.
- Breast Cancer Testing Breast cancer genomic testing and biomarker analysis for personalized therapy selection.
- Colorectal Cancer Testing Colorectal cancer diagnostic testing and biomarker insights for treatment guidance.
- Gastric Cancer Testing Gastric cancer testing solutions for molecular profiling and therapy selection.
- Gynecologic Cancer Testing Gynecologic cancer diagnostic testing and biomarker analysis for personalized care.
- Hematologic Cancer Testing Hematologic cancer testing including leukemia markers and comprehensive blood cancer diagnostics.
- Biopharma Services Drug development and clinical trial support services for biopharmaceutical partners, including biomarker discovery, cancer immunology research, and RaDaR ST for Pharma Partners.
- Oncology Data Solutions Real-world evidence and genomic data solutions providing insights from over 2 million patient profiles across 40,000 providers and 4,000 healthcare organizations.
- Lab Services Pathology laboratory services including test requisition forms, diagnostic testing workflow support, and centralized lab processing for healthcare providers.
Companies that use Clarient
Customer profileSegments3 records
Ideal customer profiles2 records
Clarient technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Clarient partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- EHR Integration PartnerscoreNeoGenomics provides EHR integration capabilities to enable seamless electronic health record connectivity for test ordering and result delivery. These integrations support Pathline clients and other healthcare providers in streamlining laboratory testing workflows.
- Biopharma PartnerscoreNeoGenomics provides biomarker discovery services and clinical trial support to pharmaceutical companies developing cancer therapies. The company contributes to cancer immunology research and helps biopharma partners accelerate drug development through their RaDaR ST for Pharma Partners program.
- Pathline ClientscorePathline is NeoGenomics' client platform enabling pathology laboratories to access NeoGenomics testing services and integrate them into their workflow.
Scale indicators5 records
Recent moves6 records
Expansion highlights4 records
Clarient competitors and assessment
Company assessmentDirect peers
- Natera: Natera operates in oncology molecular testing and MRD (Signatera), making it a direct competitor to NeoGenomics' RaDaR ST and broader molecular oncology testing menu.
- Caris Life Sciences: Caris offers molecular profiling (MI Profile) and AI-driven biomarker analysis across solid tumors, directly competing with NeoGenomics' multi-modal oncology testing menu and biopharma services.
- Tempus: Tempus provides NGS-based molecular profiling, real-world data, and biopharma services that overlap directly with NeoGenomics' PanTracer portfolio and Oncology Data Solutions offerings.
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) is a leading provider of comprehensive genomic profiling for solid tumors, directly competing with NeoGenomics' PanTracer Pro and CGP offerings across oncology providers and biopharma partners.
- Guardant Health: Guardant Health is a leader in liquid biopsy and MRD detection (Guardant360, Reveal), directly competing with NeoGenomics' liquid biopsy offering and the RaDaR ST MRD assay.
- Exact Sciences: Exact Sciences (with Thrive, Oncotype, and Precision Oncology offerings) competes in oncology molecular diagnostics and screening, overlapping with NeoGenomics' disease-state testing solutions.
Regional players
- Burning Rock Biotech: Burning Rock is a China-based oncology NGS company offering comprehensive genomic profiling; comparable in technology and biopharma service model to NeoGenomics but primarily serving the China market.
Broad incumbents
- Quest Diagnostics: Quest Diagnostics is a major clinical laboratory offering oncology and molecular testing at scale; while broader in scope, it directly competes for oncology hospital and health system send-out business.
- Laboratory Corporation of America (Labcorp): Labcorp is a national reference laboratory providing oncology and molecular diagnostics services that compete with NeoGenomics across hospital systems and community oncology practices.
Emerging players
- Strata Oncology: Strata Oncology offers molecular profiling and a clinical trial matching platform for advanced cancer patients, partially overlapping with NeoGenomics' CGP and biopharma partnership offerings.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Clarient social profiles
Digital presenceClarient financial estimates
Financial estimateRevenue estimate
Valuation estimate
Clarient leadership team
Management profileNumber of profiles
Profiles1 record
Clarient funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Clarient M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Clarient
What does Clarient do?
Clarient provides oncology testing and diagnostic services in the United States, operating as a precision oncology laboratory within NeoGenomics Laboratories. The company offers over 500 tests across major modalities — including molecular testing, immunohistochemistry (IHC), flow cytometry, FISH, DNA/RNA next-generation sequencing (NGS), and comprehensive genomic profiling (CGP) — covering both solid tumors and hematologic cancers through tissue-based, liquid biopsy, and heme tests. It supports healthcare providers with diagnostic data, therapy guidance, and predictive biomarker insights, and partners with biopharma on drug development, biomarker discovery, and clinical trial services.
Is Clarient a public or private company?
Clarient is a public company. It is classified as venture growth investor backed and is currently operating.
When was Clarient founded?
Clarient was founded in 2001. It employs 251 to 500 people.
Where is Clarient based?
Clarient is headquartered in Aliso Viejo, United States, in the North America region.
How does Clarient make money?
One revenue line is on record: laboratory Testing Services.
Who are Clarient's main competitors?
Direct peers on record are Natera, Caris Life Sciences, Tempus, Foundation Medicine, Guardant Health and Exact Sciences. Burning Rock Biotech is listed as a regional player. Broad incumbents are Quest Diagnostics and Laboratory Corporation of America (Labcorp). Strata Oncology is listed as an emerging player.
Does Clarient have an API?
No public API is recorded for Clarient.
What industry is Clarient in?
Clarient's product category is Oncology Diagnostic Services. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 621511 and its SIC code is 8071.